Methods and compositions for the treatment of cancer
Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.
1. An aptamer-siRNA chimera (AsiC) chimeric molecule comprising an Epithelial Cell Adhesion Molecule (EpCAM) binding aptamer domain and an inhibitory nucleic acid domain that inhibits Polo-like Kinase 1 (Plk1) wherein the chimeric molecule comprises the sequence of SEQ ID NO: 1 or 3.
2. The molecule of claim 1 , wherein the 3′ end of the molecule comprises dTdT.
3. The molecule of claim 1 , wherein the molecule comprises at least one 2′-F pyrimidine.
4. A pharmaceutical composition comprising the molecule of claim 1 and a pharmaceutically acceptable carrier.
5. The composition of claim 4 , comprising at least two chimeric molecules, wherein the chimeric molecules have different aptamer domains or inhibitory nucleic acid domains.
6. The composition of claim 5 , wherein different apatmer or inhibitory nucleic acid domains recognize different targets.
7. The composition of claim 5 , wherein different apatmer or inhibitory nucleic acid domains have different sequences and recognize the same target.
8. The composition of claim 4 , further comprising an additional cancer treatment.
9. The composition of claim 8 , wherein the cancer treatment is paclitaxel.